5 Best Mid-Cap Stocks to Buy Now

Page 5 of 5

1. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Market Cap as of September 2: $9.708 billion

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is an Irish biopharmaceutical company specializing in neuroscience and oncology.

75% of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s revenue is derived from its neuroscience segments, especially its sleep disorder medication. The company holds a monopoly over narcolepsy drugs. Narcolepsy has no cure, and around 150,000 to 200,000 Americans suffer from it, which means that the company will benefit from steady streams of income from the drug. According to recent reports, the company’s neuroscience sales recorded a 20% growth, while oxybate sales were 10% higher than the previous year. The oncology segment reported the most significant sales growth at 40%.

On August 5, H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares and lowered the price target to $204 from $210. The analyst believes that the company’s full-year earnings “will likely trounce guidance” if there is Xyrem generic by January.

You can also take a look at 10 Best Self-Driving Stocks To Invest In and 10 Best Affordable Tech Stocks to Invest In Now.

Page 5 of 5